Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
White House sees decision on Moderna COVID shot for kids under 5 in next few weeks
WASHINGTON, May 22 (Reuters) - White House COVID-19 response coordinator Dr. Ashish Jha said on Sunday he expects a U.S. Food and Drug Administration decision on authorizing Moderna's vaccine for children under age five within the next few weeks.
Moderna completed its application and FDA experts are looking closely at the data, Jha said on ABC's This Week with George Stephanopoulos, adding that the analysis is likely to be completed in the next few week and that a final decision would follow a meeting of the agency's expert advisers.
"So my hope is that it's going to be coming in the next few weeks," he said.
news imminent$$$$$$$$
approval this month "maybe" 6 months to 5 years, Only vaccine to do that!
Markets are heading south quickly, trying to drag this with it!!!
Here's How Moderna Could Top $450 Again-
Moderna stock could even top its record high. And here are three factors that could help that happen:
https://www.fool.com/investing/2022/05/20/heres-how-moderna-could-top-450-dollars-again/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article
WASHINGTON, May 19 (Reuters) - The U.S. Food and Drug Administration will act as soon as possible on Moderna Inc's application seeking approval of its COVID-19 vaccine for children under age 5, the agency's chief told lawmakers on Thursday.
"There's no delay in Moderna's application," FDA Commissioner Robert Califf told a U.S. House Agriculture subcommittee, adding the agency was preparing for public hearings on the company's bid "as quickly as possible."
MODERNA included in the S&P ESG index
https://www.spglobal.com/spdji/en/documents/indexnews/announcements/20210715-1419561/1419561_5alxn.pdf
Tuesday 09 November 2021 Bill Gates has warned governments to prepare for smallpox terror attacks and future pandemics by investing billions into research and development.
https://www.independent.co.uk/news/science/bill-gates-smallpox-terror-attack-b1958789.html
" the long awaited moment has come" 2022
https://www.euronews.com/next/2022/05/18/monkeypox-what-we-know-so-far-about-the-smallpox-like-virus-detected-in-the-uk
CEO Stephane Bancel opens up to Nicolai Tangen:
https://play.acast.com/s/in-good-company-with-nicolai-tangen/stephane-bancel-ceo-of-moderna
May 16, 2022. Bancel owns 21,361,198 shares of the company!!!!!!!!!
$MRNA has 46 programs in development, 29 of which are already in clinical trials. it's reasonable to expect that Moderna will be able to bring to market additional vaccines to supplement its sales and eventually replace its COVID-19-related revenue. In fact, when Moderna recently reported its first-quarter 2022 earnings, the company stated it expects to have four programs in phase 3 trials in the second quarter of this year!
IAVI AND MODERNA LAUNCH FIRST-IN-AFRICA CLINICAL TRIAL OF MRNA HIV VACCINE DEVELOPMENT PROGRAM
NEW YORK, NY and CAMBRIDGE, MA / ACCESSWIRE / May 18, 2022 / The nonprofit scientific research organization IAVI and Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the first participant screenings are soon to start for a Phase I clinical trial of an mRNA HIV vaccine antigen (mRNA-1644) at the Center for Family Health Research (CFHR) in Kigali, Rwanda, and The Aurum Institute in Tembisa, South Africa.
https://investors.modernatx.com/news/news-details/2022/IAVI-and-Moderna-Launch-First-in-Africa-Clinical-Trial-of-mRNA-HIV-Vaccine-Development-Program/default.aspx
mRNA vaccines superior to others in COVID variant antibody response, study finds-
mRNA COVID-19 vaccines manufactured by Moderna (NASDAQ:MRNA) are more effective in producing neutralizing antibodies to variants than other types, according to a new study.
The cohort study, published in PLoS Medicine, included 165 health care workers in the Netherlands vaccinated with one of the two mRNA shots
https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1003991
Next moderna!
BIG NEWS OUT: MODERNA ANNOUNCES ADVANCEMENTS IN MRNA PLATFORM SCIENCE FOR APPLICATION ACROSS MULTIPLE DISEASES AT SCIENCE AND TECHNOLOGY DAY
With Moderna's focus on respiratory diseases, the Company has invested in designing mRNA delivery systems tailored to targeting pulmonary disease. For pulmonary applications, delivery of mRNA medicines directly to the lungs by inhalation is the preferred method of administration in order to maximize the concentration of the medicine locally in the lung. Moderna researchers have developed a new LNP formulation that addresses many of the challenges associated with lung delivery of mRNA. This pulmonary LNP formulation is delivered by inhalation, uses multiple lipids, and is able to target specific areas of the lung. Moderna's optimization of pulmonary delivery of mRNA provides opportunities to address a range of unmet medical needs.
Moderna is collaborating with Vertex to deliver mRNA directly to the lungs via aerosolization to enable production of a functional cystic fibrosis (CF) transmembrane conductance regulator (CFTR) protein. CFTR is an important target for treatment because it is a defect in the CFTR gene that leads to buildup of thick mucus in the airways, chronic lung infections, inflammation and eventual respiratory failure. To date, the companies have completed IND studies that are supportive of advancing to clinical development. Vertex expects to submit an IND for this program in the second half of this year. In a second collaboration, the companies are collaborating to develop a portfolio of mRNA CF treatments, through the discovery and development of novel LNPs and mRNAs for the delivery of gene-editing therapies for the treatment of CF.
BIG COMPANY "The future is now, my friend"
https://investors.modernatx.com/news/news-details/2022/Moderna-Announces-Advancements-in-mRNA-Platform-Science-for-Application-Across-Multiple-Diseases-at-Science-and-Technology-Day/default.aspx
The incredible success of the two mRNA vaccines against COVID-19 sparked a surge of interest and investment in this new therapeutic modality. And because mRNA is infinitely programmable, scientists are now working on deploying it towards fighting many other diseases. Our customers have already embarked on this second wave, developing mRNA drugs to treat bacterial infections, rare genetic diseases, cancer and more.
https://www.fiercebiotech.com/sponsored/mrna-unlocked-how-technology-convergence-driving-next-wave
Pediatric Acute Liver Failure Due to Type 2 Autoimmune Hepatitis Associated With SARS-CoV-2 Infection: A Case Report
https://journals.lww.com/jpgnr/Fulltext/2022/05000/Pediatric_Acute_Liver_Failure_Due_to_Type_2.29.aspx
MODERNA TO HOST ANNUAL SCIENCE AND TECHNOLOGY DAY ON MAY 17, 2022
it has always been like that, it is not a new thing!
Moderna and former Dentsply Sirona CFO sign 'claw back' agreement on $700K severance
Moderna Inc. and former CFO Jorge Gomez have agreed the company can claw back his $700,000 severance if Gomez “is found to have engaged in any wrongdoing or is required to pay a fine” related to Dentsply Sirona Inc.’s securities fraud investigation.
https://www.bizjournals.com/charlotte/news/2022/05/16/moderna-clawback-cfo-dentsply-sirona-sec-violation.html?ana=yahoo
mrna does not give money away!
People Diagnosed With Cancer Benefit From Moderna COVID-19 Vaccine
https://www.breastcancer.org/research-news/people-diagnosed-with-cancer-benefit-from-moderna-covid-19-vaccine
Evaluation of Antibody Response to SARS-CoV-2 mRNA-1273 Vaccination in Patients With Cancer in Florida
https://jamanetwork.com/journals/jamaoncology/fullarticle/2790099
Mar 30, 2022 - BlackRock Inc. has filed an SC 13G form with the Securities and Exchange Commission (SEC) disclosing ownership of 28,671,935 shares of Moderna Inc
In their previous filing dated 2021-07-12 , BlackRock Inc. had reported owning 19,390,725 shares!!!!!!!!!
that says it all .......
Moderna prepares to sell COVID-19 vaccine privately as US delays booster call
CMS [Centers for Medicare & Medicaid Services] has basically come up saying for fiscal year 2023, which starts in October, the price for COVID-19 vaccines should be around $60," Bancel said.
https://finance.yahoo.com/news/moderna-prepares-to-sell-covid-19-vaccine-privately-as-us-delays-booster-call-162911397.html
Share Repurchase Program: As announced last quarter, the Board of Directors authorized a share repurchase program for $3 billion in February 2022 to return excess capital to shareholders. The previous program of $1 billion announced in August 2021 has been fully utilized as of the end of January 2022.
Cash Used for Repurchase of Common Stock: Cash used for repurchases of common stock was $623 million for the three months ended March 31, 2022. Moderna did not conduct share repurchases prior to the fourth quarter of 2021. From the end of the third quarter of 2021 to the end of the first quarter of 2022, the Company repurchased 7 million shares, reducing the number of common shares outstanding from 405 million to 400 million, more than offsetting 2 million shares of common stock issued in connection with equity compensation over this period.
Switzerland gives green light to Moderna's Covid vaccine for 6-11 year olds
https://www.swissinfo.ch/eng/switzerland-gives-green-light-to-moderna-s-covid-vaccine-for-6-11-year-olds/47591096
$MRNA upcoming event May 17: Science and Technology Day. Options expiring on May 20 that cover the event have an implied move of ±8.8%
DO YOU WANT TO KNOW WHAT HAPPENS WITHOUT VACCINES? TAKE A LOOK AT WHAT IS HAPPENING IN NORTH KOREA WHERE COVID IS RELEASING!!!!!!!
https://www.bbc.com/news/world-asia-61450255
The Mainichi Shimbun answers some common questions readers may have about the quick development of COVID-19 vaccines.
What diseases can it be used against?
- It is especially promising as a vaccine against cancer. Development of treatment that effectively acts against genes unique to cancer cells is under deliberation, and in Germany and the United States, research is at the stage of examining their efficacy on patients. Theoretically speaking, the vaccines are thought to be capable of use against all types of cancer, and their application against other diseases is also under consideration.
https://mainichi.jp/english/articles/20220512/p2a/00m/0op/017000c
There is no doubt Moderna is one of the best Biotech!
Food and Drug Administration (FDA) plan to meet as late as the end of June to figure out which variants of the virus should be targeted with boosters intended for use in the fall.
-May 4 the U.S. government hasn't allocated money in the budget to buy booster doses of any version of Spikevax for the anticipated fall surge. If this situation doesn't resolve soon, to continue selling its jab, the biotech could sell it directly to individuals, pharmacies, and insurers.
the price per dose for the 2023 fiscal year could be in the $60 range. That's quite an increase compared to the price of around $16.50 per dose that the U.S. government has paid the company since the start of the pandemic.
$MRNA money machine!!!!!!!!
Winner!!!!!
They have one of the better pipelines in the industry and 20 billion in cash. They could buy drugs that are already producing revenue!!!!!!!!!
I smell something burning!
A fourth dose of an mRNA vaccine significantly boosts the immune protection from the coronavirus in all ages, according to new research published Tuesday in the Lancet Infectious Diseases journal!
https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(22)00271-7/fulltext
$MRNA
there are two of us then!
past water no longer grinds!
2021 October "is old news"
40% of its market cap in cash!
$MRNA
Moderna’s coronavirus vaccine is safe and effective at preventing Covid-19 in children aged six to 11, according to a peer reviewed study published in the New England Journal of Medicine on Wednesday, as the Food and Drug Administration considers expanding access to the shots for younger children.
https://www.nejm.org/doi/full/10.1056/NEJMoa2203315
Moderna Inc has made all necessary submissions required by the U.S. Food & Drug Administration for emergency use authorization of its COVID-19 vaccine in adolescents and children, it said on Wednesday.
https://news.alertsandnews.com/moderna-completes-fda-submission-for-use-of-covid-shot-in-adolescents-kids/
These shares trade like the company makes no money. LOL
relax
mRNA technology may have potential to repair, regenerate cardiac tissue
https://www.healio.com/news/cardiology/20220505/mrna-technology-may-have-potential-to-repair-regenerate-cardiac-tissue
$MRNA